Rhabdomyosarcoma Clinical Trials 2024

Rhabdomyosarcoma Clinical Trials 2024

Rhabdomyosarcoma research studies recruiting patients in 2024 need your help. Receive premium care & cutting edge treatments by enrolling in rhabdomyosarcoma clinical trials today.

Trials for RMS Patients

Trials for Ewing Sarcoma Patients

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to rhabdomyosarcoma

What are the top hospitals conducting rhabdomyosarcoma research?

In the battle against rhabdomyosarcoma, a rare form of cancer that primarily affects children, hospitals across the United States are leading the charge in clinical trials. In sunny Los Angeles, Children's Hospital Los Angeles takes center stage with an impressive 20 ongoing trials dedicated to rhabdomyosarcoma and a noteworthy history of 40 completed studies. This renowned institution began its journey into rhabdomyosarcoma research in 1997, setting the stage for groundbreaking advancements in treatment options. Similarly committed to fighting this aggressive disease is Children's Hospital Colorado in Aurora, which also boasts 20 active clinical trials and has conducted 31 previous studies since their first recorded trial in 1999.

On the East Coast, Children's National Medical Center located in Washington D.C., proudly contributes to this vital effort with its own portfolio of 20 ongoing rhabdomyosarcoma trials and an impressive tally of 42 previously conducted studies dating back to their inaugural trial in 1997. Heading further south to Saint Petersburg, Florida, Johns Hopkins All Children's Hospital showcases their dedication through a commendable count of18 active clinical trials targeting rhabdomyosarcoma and having already accomplished25 earlier investigations since initiating their first trial backin1999.

Finally making its mark from Saint Louis is Washington University School of Medicine where they currently run eighteen hailed experiments around this condition ontopof conducting thirty-sixtrials across various periods until today commenced way backtothe early months during short years postmillennium; specifically startingfromtheir veryfirst operationwhich dates as farbackas earlyyears ranging between19th century being17-25years!

These leading hospitals stand as beacons of hope for children facing the challenges posed by rhabdomyosarcoma. Through collaborative efforts among medical professionals and researchers nationwide at these institutions—spanning coast-to-coast—we witness firsthand how perseverance coupled with cutting-edge research brings us closer to conquering this formidable disease. With each trial conducted and breakthrough achieved, these hospitals provide renewed optimism for a brighter future where rhabdomyosarcoma becomes a thing of the past

Which are the best cities for rhabdomyosarcoma clinical trials?

When it comes to rhabdomyosarcoma clinical trials, several cities emerge as leading research hubs. New york, with 54 active trials, offers studies on various treatments like Palbociclib and Ivosidenib. Orlando follows closely with 49 ongoing trials exploring pharmacological studies and targeted therapies such as Vemurafenib. Saint Louis stands out with 48 active trials focusing on similar investigations. Additionally, Los Angeles and Chicago both contribute significantly to rhabdomyosarcoma research through their respective centers conducting multiple studies on a range of treatment options. Through these cities' collective efforts, individuals affected by rhabdomyosarcoma have access to cutting-edge clinical trials that hold promise for improved outcomes in the future.

Which are the top treatments for rhabdomyosarcoma being explored in clinical trials?

Exciting advancements are being made in the exploration of clinical trials for rhabdomyosarcoma, a rare form of cancer that primarily affects children. Among the top treatments currently under investigation are:

  • Palbociclib: With 2 active trials and 3 all-time rhabdomyosarcoma trials since its listing in 2017, this drug shows promise as a potential treatment option.
  • Proton Beam Radiation: Also involved in 2 ongoing trials and first listed back in 2004, proton beam radiation is gaining attention for its targeted application against rhabdomyosarcoma.
  • Pharmacological Study: Engaging in 2 active and10 all-time rhabdomyosarcoma trials since its introduction in 2010, this study aims to identify new pharmaceutical approaches to combat the disease.
  • Olaparib: This drug has shown potential with its involvement in 2 current trials and an additional three over time since it was first listed as a treatment option for rhabdomyosarcoma patients starting from year perspective (2013).

These ongoing research efforts carry hope for improved outcomes and brighter futures for those affected by rhabdomyosarcoma.

What are the most recent clinical trials for rhabdomyosarcoma?

Promising developments have emerged in recent clinical trials for rhabdomyosarcoma, offering hope to those affected by this rare cancer. Among the notable studies is a trial focusing on individuals with intermediate-risk rhabdomyosarcoma, evaluating potential treatment options through Phase 1 and Phase 2 stages (since September 1, 2023). Another exciting avenue being explored involves CARE T cells, which show potential as an innovative therapy for rhabdomyosarcoma patients in early-phase clinical trials (since July 3, 2023). Additionally, researchers are investigating the efficacy of atezolizumab—a novel immunotherapy—in treating this aggressive form of cancer through combined Phase 1 and Phase 2 trials (since April 18, 2023). The study involving liposomal doxorubicin aims to assess its effectiveness against rhabdomyosarcoma in a Phase I trial setting (since January 24,2023), while another ongoing clinical trial explores targeted therapies specifically designed for patients with relapsed or refractory high-grade glioma and rhabdomyosarcoma cohorts during their respective phases (available since December27 ,2022).

What rhabdomyosarcoma clinical trials were recently completed?

Recent advancements in rhabdomyosarcoma clinical trials have shown promising developments in the fight against this aggressive cancer. In May 2018, David Wald completed a trial investigating ALT803 as a potential treatment option. Additionally, Eisai Inc.'s trial testing Eribulin mesylate concluded in April 2018, providing valuable insights into its effectiveness. Notably, OHSU Knight Cancer Institute conducted a Pharmacological Study that wrapped up in March 2017 and Baylor College of Medicine's TAA-Specific CTLs trial reached completion in April 2015. These significant milestones highlight the ongoing efforts to find innovative therapeutic approaches for patients battling rhabdomyosarcoma and offer hope for improved outcomes.